SCHEDULE 13G/A: Adage Capital Management Discloses 7.70% Stake in ProQR Therapeutics N.V.

Adage Capital Management, L.P., along with Robert Atchinson and Phillip Gross, has disclosed a beneficial ownership of 7.70% of ProQR Therapeutics N.V.'s Ordinary Shares as of March 31, 2025.

Summary

• Adage Capital Management, L.P., Robert Atchinson, and Phillip Gross collectively reported beneficial ownership of 8,102,098 Ordinary Shares of ProQR Therapeutics N.V.
• This ownership represents 7.70% of the total 105,212,527 Ordinary Shares outstanding as of December 31, 2024, as reported in the Company's Annual Report on Form 20-F.
• The filing is an Amendment No. 1 to a Schedule 13G, indicating an update to a previously reported ownership stake.
• The Reporting Persons certify that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of ProQR Therapeutics N.V.

Sentiment

Score: 6

Explanation: The document is a routine ownership disclosure (Schedule 13G Amendment), which is neutral in sentiment. A score of 6 reflects the continued significant ownership by a major institutional investor, which can be seen as a minor positive signal of confidence, but the filing itself does not contain new positive or negative operational information.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, which can influence investor perception and liquidity.

Key Dates

Keywords

ProQR Therapeutics N.V., Adage Capital Management, Schedule 13G, Beneficial Ownership, Ordinary Shares, Institutional Investor, SEC Filing, Ownership Disclosure